Hospitalization by ACS patient with type II diabetes.
Conditions
Interventions
Migtol administrated group: 48 hours after CGM, 50mg migtol will be administrated 3 days in a day before each meal. It will be continued for 6 months.
- Non administrated group: continue ordinary trea
Sponsors
Department of Cardiovascular Medicine, Saga University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Patients who are hospitalized for ACS such as cardiac infarction, unstable angina. (within 7days of onset) (2) (3)Type II diabetes:Patients with less 9 % of HbA1c(JDS) (4)Age: older than 20 and less than 80-year-old when agreement is acquired. (5)Gender:regardless (6)Patient with full understanding of this study and agrees with written consent. The agreement must be based on the patients' free will.
Exclusion criteria
Exclusion criteria: (1)patient suspected of type I diabetes mellitus (2)patient under insulin treatment (3)Patient who has already taking alpha-Gl. (4)patient with serious liver disease (5)patient with history of type B or C hepatitis. (6)patients with serious kidney disease, and whose serum creatinine level is higher than 2.0mg/dL (7)patient with history of digestive system operation, such as gastric resection (8) Patients with history of allergy and hypersensitivity (9)Pregnant and/or breathbeeding, child-bearing potential women. (10)blood glucose level is more than 400mg/dL or less than 40mg/dL (11)patients who was diagnosed that his/her condition is not appropriate to join this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Short Term Evaluation Compare the blood glucose level of biomarkers including inflammatory, CBM, cardiac and renal functions through the hospitalization. (before and after the inserting CGM) 2)Long Term Evaluation Evaluate the data taken 1months and 3 months and 6 months after the medication. The cardiac event, glucose tolerance, lipid,renal fanction,echocardiography, biomarker, and blood vessel function tests will be compared. | — |
Countries
Japan
Contacts
Public ContactKoichi Node, MD. PhD.
Saga Univerisity Department of Cardiovascular Medicine
Outcome results
None listed